Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The aim of the present studies was to design a once weekly GLP-1 analogue by increasing albumin affinity and secure full stability against metabolic degradation. The fatty acid moiety and the linking chemistry to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analogue. Semaglutide was selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased. The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs. Semaglutide is currently in phase 3 clinical testing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The elimination half-life of 7 (Table 2), as measured after i.v. dose in minipigs, could be increased by nearly 40% through the replacement of the C18 diacid protractor with a C20 diacid (8), providing an even more attractive PK profile for potential once-weekly clinical administration when compared to the once-weekly GLP-1R agonist semaglutide [47].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [47]
In the citing paper
“We estimated the required sample size to be 60 participants (30 for oral and 30 for subcutaneous semaglutide), assuming a two-sided hypothesis test with a 95% confidence level and accounting for a potential 10% loss. This estimation was based on a minimum clinically relevant difference of -10% in fat body mass at the conclusion of the follow-up (22, 23).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [22]
In the citing paper
“Semaglutide, a GLP-1 analogue with an extended half-life of approximately 1 week (which permits once-weekly subcutaneous administration), 4”
From Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016) · cites this paper as [4]
In the citing paper
“The long half-life of semaglutide (approximately 7.5 hours in mice, 12 hours in rats, and 183 hours in humans) makes it suitable for once-weekly administration in humans (43, 48–50).”
From The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission (2023) · cites this paper as [48]
In the citing paper
“This formulation results in slower degradation and a half-life 155 to 184 hours, allowing for once-weekly subcutaneous dosing without compromising weight loss efficacy.(11, 26)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [26]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Schuck, P. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76713-0 · Cited by 3,868
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Fatty acid binding to plasma albumin
Spector, A. A. (1975) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36723-7 · Cited by 966
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Self-citationAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Fatty acid binding to human serum albumin: new insights from crystallographic studies
Curry, S., Brick, P., & Franks, N. P. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00148-1 · Cited by 495
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Research works printed but not linked: 1
- 10.1016/s0140-6736(09)60659-0 · DOI · Paper page
Cited by
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Additionally, the palmitic (C16:0) fatty monoacid in liraglutide is exchanged to dicarboxylic-stearic acid (C18:0), and the link to this diacid-based fatty acid is extended relative to that in liraglutide with a synthetic spacer repeat [896].”
BackgroundThe Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“35,104,116 On August 22, 2022, Novo Nordisk announced the primary results of the Phase II clinical trial for the dual-action compound CagriSema, which demonstrated effective blood sugar reduction and weight loss.”
BackgroundRubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
“Semaglutide’s half-life is 165 hours, resulting from an amino acid replacement (preventing dipeptidyl peptidase 4 degradation) and a C18 fatty diacid addition.(7,8) In a phase 2 trial, once-daily subcutaneous semaglutide, 0.”
BackgroundThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
“Preclinical methodology GIP, GLP-1, LY3298176 (C225H348N48O68), semaglutide [39], a longacting GIPR agonist (LA-GIPRA), and [d-Ala(2)]GIP [40] were synthesized at Eli Lilly and Company using traditional peptide chemistry methods and solubilised in PBS, with the exception of [d-Ala(2)]GIP which was formulated in TriseH…”
MethodPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717
“12 hours) and full dipeptidyl peptidase-4 stability (2).”
BackgroundSelf-citationBlundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
“Semaglutide has 94% structural homology with native human GLP-1(13) with three important modifications: an amino acid substitution at position 8 makes semaglutide less susceptible to degradation by dipeptidyl peptidase-4; lysine acylation of the peptide backbone with a spacer and C-18 fatty di-acid chain at position 2…”
BackgroundAdvances in oral peptide therapeutics
Drucker, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0053-0 · Cited by 646
Harnessing albumin as a carrier for cancer therapies
Hoogenboezem, E. N., & Duvall, C. L. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.011 · Cited by 610
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
“mology to native human GLP-1 and is structurally similar to liraglutide (10), but important structural modifications make it less susceptible to degradation by dipeptidyl peptidase-4 and increase its specific high-affinity binding to albumin (10).”
BackgroundTranscellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist
Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7047 · Cited by 553
“In line with this, recent advancements in fatty acid acylation– based protraction technology have provided the possibility of achieving extended plasma half-lives (t1⁄2) without increasing molecular size, leading to the discovery of semaglutide, a GLP-1 analog with a t1⁄2 of ~1 week in humans (8).”
BackgroundSelf-citationGlucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
“In the presence of HSA, TZP right-shifts 81-fold (n = 5), while the potency of GLP-1(7-36) is unaltered (n = 24).”
InfluentialRakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509
“= Western diet L iraglutide (1) and semaglutide (2) are longacting analogs of the human glucagon like peptide (GLP)-1 incretin hormone, with 97% and 94% amino acid homology, respectively, and were engineered using fatty acid acylation to facilitate serum albumin binding to increase their plasma half-life.”
MethodSelf-citationAhrén, B., Masmiquel, L., Kumar, H., Sargin, M., Karsbøl, J. D., Jacobsen, S. H., & Chow, F. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30092-x · Cited by 495
Aroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30085-2 · Cited by 464
Peptides as a platform for targeted therapeutics for cancer: peptide–drug conjugates (PDCs)
Cooper, B. M., Iegre, J., O' Donovan, D. H., Ölwegård Halvarsson, M., & Spring, D. R. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00556h · Cited by 414
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412
“These modifications result in a half-life of ;1 week (15), enabling onceweekly subcutaneous administration (17, 18).”
BackgroundCapehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412
Gilbert, M. P., & Pratley, R. E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00178 · Cited by 407
“Sitagliptin Semaglutide is a GLP-1RA with 94% homology to native GLP-1 (61).”
BackgroundInfluentialGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
“In a phase 2 study over 12 weeks, semaglutide dose-dependently reduced HbA1c and body weight, with higher doses being more effective than liraglutide (Nauck and Sesti, 2012; Trujillo and Nuffer, 2014; Lau et al., 2015).”
BackgroundSelf-citationIntestinal permeation enhancers for oral peptide delivery
Maher, S., Mrsny, R. J., & Brayden, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.005 · Cited by 381
Recent trends in protein and peptide-based biomaterials for advanced drug delivery
Varanko, A., Saha, S., & Chilkoti, A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.008 · Cited by 369
“A notable example of this class is Semaglutide, an FDA approved drug that is a glucagonlike peptide-1 (GLP-1) analog with an octadecyl fatty diacid conjugated to the epsilon amineof a lysine residue in thepeptide via a glutamyl ethylene glycol spacer [153].”
RCSB Protein Data Bank: Enabling biomedical research and drug discovery
Goodsell, D. S., Zardecki, C., Di Costanzo, L., Duarte, J. M., Hudson, B. P., Persikova, I., Segura, J., Shao, C., Voigt, M., Westbrook, J. D., et al. (2020) · Protein Science · doi:10.1002/pro.3730 · Cited by 353
“GLP1-R 37 is the target of six oligopeptide agonists (exenatide [PDB 3c59, 3c9t], 38 liraglutide [4apd], 39 lixisenatide, albiglutide, dulaglutide, and semaglutide [4zgm] 40 ) approved by the US FDA for treatment of type II diabetes mellitus.”
BackgroundMaterials and methods for delivery of biological drugs
Zelikin, A. N., Ehrhardt, C., & Healy, A. M. (2016) · Nature Chemistry · doi:10.1038/nchem.2629 · Cited by 315
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
Prodrugs in medicinal chemistry and enzyme prodrug therapies
Walther, R., Rautio, J., & Zelikin, A. N. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.013 · Cited by 288
Aroda, V. R., Ahmann, A., Cariou, B., Chow, F., Davies, M. J., Jódar, E., Mehta, R., Woo, V., & Lingvay, I. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.12.001 · Cited by 296
“Semaglutide has 94% amino acid sequence homology with native human GLP-1, with several modifications that enable increased binding of albumin and slowed degradation in plasma [24].”
BackgroundEmerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
“which is 2-aminoisobutyric acid (AIB), aiming to inhibit degradation by DPP-4 [49].”
BackgroundAdvances in therapeutic peptides targeting G protein-coupled receptors
Davenport, A. P., Scully, C. C. G., de Graaf, C., Brown, A. J. H., & Maguire, J. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0062-z · Cited by 275
“Glucagon GLP-1 Exendin (9-39); antagonist Congenital hyperinsulinism, postbariatric hypoglycaemia 2018 None”
BackgroundTargeting GLP-1 receptor trafficking to improve agonist efficacy
Jones, B., Buenaventura, T., Kanda, N., Chabosseau, P., Owen, B. M., Scott, R., Goldin, R., Angkathunyakul, N., Corrêa Jr, I. R., Bosco, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03941-2 · Cited by 272
“Greater insulin release with exendin-phe1 was unlikely to result from cross-reactivity with other incretin receptors, as it was blocked with the GLP-1R orthosteric antagonist exendin(9-39) (Supplementary Fig.”
InfluentialMechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254
Ryan, D. H., Lingvay, I., Colhoun, H. M., Deanfield, J., Emerson, S. S., Kahn, S. E., Kushner, R. F., Marso, S., Plutzky, J., Brown-Frandsen, K., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.07.008 · Cited by 249
Anti-diabetic drugs recent approaches and advancements
Dowarah, J., & Singh, V. P. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115263 · Cited by 227
Hjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13120 · Cited by 245
“Semaglutide has 94% structural homology with native human GLP-1(21,22) with 3 important modifications: an amino acid substitution at position 8 that makes it less susceptible to degradation by dipeptidyl peptidase-4; lysine acylation of the peptide backbone, with a spacer and C-18 fatty di-acid chain at position 26 th…”
BackgroundDiabetes Mellitus and Heart Failure
Lehrke, M., & Marx, N. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.014 · Cited by 236
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014879117 · Cited by 231
“(B and C) The signal transduction pharmacology of LY3502970 and GLP-1(7-36) was determined.”
BackgroundSemaglutide for the treatment of obesity
Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.008 · Cited by 227
Fu, C., Yu, L., Miao, Y., Liu, X., Yu, Z., & Wei, M. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.07.020 · Cited by 209
Jensterle, M., Rizzo, M., Haluzík, M., & Janež, A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02153-x · Cited by 215
“once daily administration of liraglutide [5].”
Chuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.170671 · Cited by 214
Husain, M., Bain, S. C., Jeppesen, O. K., Lingvay, I., Sørrig, R., Treppendahl, M. B., & Vilsbøll, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13955 · Cited by 209
“), or once daily orally when co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (commonly known as ‘SNAC’).(12,13) The half-life (~7 days) and clinical effects of semaglutide are similar irrespective of mode of administration.”
BackgroundImpact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics
Ding, Y., Ting, J. P., Liu, J., Al-Azzam, S., Pandya, P., & Afshar, S. (2020) · Amino Acids · doi:10.1007/s00726-020-02890-9 · Cited by 200
“In taspoglutide, an analog of GLP-1, 2-aminoisobutyric acid (Aib) substitution at positions 8 and 35 prevented proteolytic cleavage by DDP-4, plasmin, and plasma kallikrein (Sebokova et al.”
BackgroundInfluentialAnti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
“A dicarboxylic-stearic acid (C18:0) is linked to the lysine 20 residue through a g glutamic acid spacer in a chemical manner that enhances the noncovalent binding to albumin to further decelerate renal clearance (Lau et al., 2015).”
BackgroundDiabetes Mellitus and Heart Failure
Lehrke, M., & Marx, N. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.010 · Cited by 188
Half‐Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation
van Witteloostuijn, S. B., Pedersen, S. L., & Jensen, K. J. (2016) · ChemMedChem · doi:10.1002/cmdc.201600374 · Cited by 183
Battle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 180
Jensen, L., Helleberg, H., Roffel, A., van Lier, J. J., Bjørnsdottir, I., Pedersen, P. J., Rowe, E., Derving Karsbøl, J., & Pedersen, M. L. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.03.020 · Cited by 182
GLP-1/glucagon receptor co-agonism for treatment of obesity
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175
“Similar to liraglutide, semaglutide (Novo Nordisk) is a fatty-acylated GLP-1 analogue with a stearic-diacid at lysine position 20, linked via a di-aminoethoxy, γ-glutamic acid spacer, and an aminoisobutyric residue at position 2 to provide protection from DPP-IV degradation [28].”
BackgroundZhang, L., Zhang, L., Li, L., & Hölscher, C. (2019) · Journal of Parkinson's Disease · doi:10.3233/jpd-181503 · Cited by 173
“Semaglutideisamodificationofliraglutidethatis protease-resistantbychangingtheaminoacidatposi-tion8andanextendedspacerfortheattachedfatty acid[32],andisonthemarketasanewonce-weekly drugtotreattypeIIdiabetes.”
Cummings, J. L., Atri, A., Feldman, H. H., Hansson, O., Sano, M., Knop, F. K., Johannsen, P., León, T., & Scheltens, P. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01666-7 · Cited by 168
Recent advances in the development of therapeutic peptides
Fetse, J., Kandel, S., Mamani, U., & Cheng, K. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.04.003 · Cited by 179
Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09699-1 · Cited by 166
“Based on the pharmacokinetic studies on Göttingen mini pig model (for moderate insulin deficiency & diabetes) and in vivo efficacy in anti-hyperglycaemic and body weight lowering effect on obese, hyper-insulinemic db/db mice model (for type 2 diabetes), semaglutide was chosen to be a clinical trial candidate [27].”
BackgroundLeiter, L. A., Bain, S. C., Hramiak, I., Jódar, E., Madsbad, S., Gondolf, T., Hansen, T., Holst, I., & Lingvay, I. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0871-8 · Cited by 159
Semaglutide as a promising antiobesity drug
Christou, G. A., Katsiki, N., Blundell, J., Fruhbeck, G., & Kiortsis, D. N. (2019) · Obesity Reviews · doi:10.1111/obr.12839 · Cited by 159
“Semaglutide represents a next‐generation GLP‐1 RA with a longer half‐life than liraglutide [183 vs 11‐15 h, respectively, after subcutaneous (sc) administration].(16,27) The modifications of the chemical structure of semaglutide from that of the native human GLP‐1 include not only two amino acid substitutions at posit…”
BackgroundA review of lipidation in the development of advanced protein and peptide therapeutics
Menacho‐Melgar, R., Decker, J. S., Hennigan, J. N., & Lynch, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.032 · Cited by 169
“In fact, screening different linkers can completely compensate for the potency loss of attaching long fatty acids [33,47].”
BackgroundMethodInfluentialNew Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Jastreboff, A. M., & Kushner, R. F. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-014919 · Cited by 158
Chemical Strategies for Half-Life Extension of Biopharmaceuticals: Lipidation and Its Alternatives
Bech, E. M., Pedersen, S. L., & Jensen, K. J. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00226 · Cited by 157
Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist
Bucheit, J. D., Pamulapati, L. G., Carter, N., Malloy, K., Dixon, D. L., & Sisson, E. M. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0185 · Cited by 156
“7,8 The amino acid substitution from alanine to alpha-aminoisobutyric acid at position 8 makes semaglutide resistant to systemic degradation by dipeptidyl peptidase-IV (DPP-IV).”
InfluentialGibbons, C., Blundell, J., Tetens Hoff, S., Dahl, K., Bauer, R., & Bækdal, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14255 · Cited by 149
Zhao, F., Zhou, Q., Cong, Z., Hang, K., Zou, X., Zhang, C., Chen, Y., Dai, A., Liang, A., Ming, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28683-0 · Cited by 149
“The cells were then infected with BRIL-TEV-2GSA-GIPR(22-421)T345F-15AA-LgBiT-TEVOMBP-MBP, DNGαs, Gβ1-peptide 86 and Gγ2, respectively, at a ratio of 1:3:3:3.”
MethodInfluentialNext generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152
“campaign: introduce GcgR potency into the molecule without sacrificing the GLP-1R and GIPR potency of 4; and protract time-action through acylation with a fatty diacid, inspired by once-weekly acylated peptides such as semaglutide [47] and tirzepatide [35].”
BackgroundMethodInfluentialA Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Drugs · doi:10.1007/s40265-021-01499-w · Cited by 160
“GLP-1 analog with increased albumin affinity and security against metabolic degradation [21].”
BackgroundAn update on the importance of plasma protein binding in drug discovery and development
Di, L. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1961741 · Cited by 148
“GLP-1 receptor agonist peptide characteristics [83,91].”
BackgroundDerivatization with fatty acids in peptide and protein drug discovery
Kurtzhals, P., Østergaard, S., Nishimura, E., & Kjeldsen, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00529-w · Cited by 151
Hall, S. F., Isaacs, D. M., & Clements, J. N. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0668-z · Cited by 142
Aroda, V. R., Blonde, L., & Pratley, R. E. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09735-8 · Cited by 135
“6 Da) is a human GLP-1 analog, similar to liraglutide but engineered to have increased albumin affinity and resistance to dipeptidyl peptidase-4 (DPP-4) inhibitor degradation to permit once-weekly subcutaneous administration [12, 23].”
BackgroundStructural determinants of dual incretin receptor agonism by tirzepatide
Sun, B., Willard, F. S., Feng, D., Alsina‐Fernandez, J., Chen, Q., Vieth, M., Ho, J. D., Showalter, A. D., Stutsman, C., Ding, L., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116506119 · Cited by 136
“, The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist.”
BackgroundMethodInfluentialKaku, K., Yamada, Y., Watada, H., Abiko, A., Nishida, T., Zacho, J., & Kiyosue, A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13218 · Cited by 132
“It has 94% homology to native GLP-1,(11) and is structurally similar to liraglutide,(12) but has modifications resulting in a half-life of ~1 week, making semaglutide appropriate for once-weekly administration.(11,12) Semaglutide has been evaluated in the Semaglutide Unabated Sustainability in Treatment of Type 2 Diab…”
BackgroundExtending the Structural View of Class B GPCRs
de Graaf, C., Song, G., Cao, C., Zhao, Q., Wang, M.-W., Wu, B., & Stevens, R. C. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.10.003 · Cited by 133
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
Granhall, C., Søndergaard, F. L., Thomsen, M., & Anderson, T. W. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0649-2 · Cited by 135
“The substitution at position 8 renders semaglutide less susceptible to degradation by dipeptidyl peptidase-4 (DPP-4), while the lysine acylation improves binding to albumin [4].”
BackgroundLong-Acting Growth Hormone Preparations – Current Status and Future Considerations
Miller, B. S., Velazquez, E. P., & Yuen, K. C. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz149 · Cited by 134
Bioactive peptides with antidiabetic properties: a review
Yan, J., Zhao, J., Yang, R., & Zhao, W. (2019) · International Journal of Food Science & Technology · doi:10.1111/ijfs.14090 · Cited by 137
Plant-Derived Bioactive Peptides: A Treatment to Cure Diabetes
Patil, S. P., Goswami, A., Kalia, K., & Kate, A. S. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09899-z · Cited by 138
“Oral delivery of the peptides is explored in past years but limits its use as peptides are degraded in the GIT tract (Lau et al. 2015).”
BackgroundLombardi, L., Genio, V. D., Alberício, F., & Williams, D. R. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00989 · Cited by 144
Development of Cagrilintide, a Long-Acting Amylin Analogue
Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A. M. K., Jeppesen, C. B., Dornonville de la Cour, C., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00565 · Cited by 129
Self-citationThe Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 129
Therapeutic Peptides: Recent Advances in Discovery, Synthesis, and Clinical Translation
Zheng, B., Wang, X., Guo, M., & Tzeng, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115131 · Cited by 140
“To overcome this, rational engineering strategies—including amino acid substitution (Ala 8 → Gly), fatty acid conjugation, and albumin-binding motifs—have yielded long-acting analogs such as liraglutide (half-life: 13 h) and semaglutide (half-life: 7 days) [17,18].”
Rosen, C. J., & Ingelfinger, J. R. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2500106 · Cited by 129
Kapitza, C., Dahl, K., Jacobsen, J. B., Axelsen, M. B., & Flint, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4289-0 · Cited by 126
“Important structural modifications make semaglutide more resistant to degradation by dipeptidyl peptidase-4 and improve binding to albumin [16].”
BackgroundGlucagon‐like peptide agonists: A prospective review
Mariam, Z., & Niazi, S. K. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.462 · Cited by 130
“36 Although their administration intervals and doses may vary, both are well-tolerated and effective for weight loss.”
BackgroundJi, L., Dong, X., Li, Y., Li, Y., Lim, S., Liu, M., Ning, Z., Rasmussen, S., Skjøth, T. V., Yuan, G., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14232 · Cited by 113
“These modifications prolong its half-life through enhanced binding to albumin and inhibition of degradation by DPP-4, facilitating once-weekly dosing.(18) The efficacy and safety of semaglutide have been established in more than 10 000”
BackgroundChen, X., Mietlicki‐Baase, E. G., Barrett, T. M., McGrath, L. E., Koch‐Laskowski, K., Ferrie, J. J., Hayes, M. R., & Petersson, E. J. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08417 · Cited by 121
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 131
“70 In addition, alanine at the 8 th position is substituted with 2-amino isobutyric acid in semaglutide, which increases the drug’s resistance to DPP-4 (Figure 1F).”
An update on peptide-based therapies for type 2 diabetes and obesity
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170939 · Cited by 111
Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety
He, R., Finan, B., Mayer, J. P., & DiMarchi, R. D. (2019) · Molecules · doi:10.3390/molecules24101855 · Cited by 118
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
Delivering on the promise of protein degraders
O’Brien, M. N., Luthra, S. A., Brown, M. F., & Bartlett, D. W. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00652-2 · Cited by 113
Marty, V. N., Farokhnia, M., Munier, J. J., Mulpuri, Y., Leggio, L., & Spigelman, I. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.599646 · Cited by 113
Cyclic Peptides in Pipeline: What Future for These Great Molecules?
Costa, L., Sousa, E., & Fernandes, C. (2023) · Pharmaceuticals · doi:10.3390/ph16070996 · Cited by 115
Albumin-based delivery systems: Recent advances, challenges, and opportunities
Murphy, G., Brayden, D. J., Cheung, D. L., Liew, A., Fitzgerald, M. T., & Pandit, A. S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.035 · Cited by 119
Semaglutide: First Global Approval
Dhillon, S. (2018) · Drugs · doi:10.1007/s40265-018-0871-0 · Cited by 104
“Compared with human GLP-1, semaglutide has two amino acid substitutions and is derivatized at lysine 26 with a hydrophilic spacer and a C18 fatty di-acid, which result in increased albumin affinity [4, 9].”
BackgroundHölscher, C. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109952 · Cited by 108
“The main target in this drug development is to enhance the survival time in the blood to maximize efficacy in treating diabetes (Dong et al., 2022; Lau et al., 2015).”
Yang, X., Feng, P., Zhang, X., Li, D., Wang, R., Ji, C., Li, G., & Hölscher, C. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107748 · Cited by 103
Peptide Lipidation – A Synthetic Strategy to Afford Peptide Based Therapeutics
Kowalczyk, R., Harris, P. W. R., Williams, G. M., Yang, S., & Brimble, M. A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-66095-0_9 · Cited by 109
“Semaglutide is the once-weekly GLP-1(7-37) analogue currently in phase 3 clinical development for the treatment of type 2 diabetes (Lau et al. 2015; Nauck et al. 2016).”
BackgroundInfluential
Metadata
- Authors
- Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., Strauss, H. M., Gram, D. X., Knudsen, S. M., Nielsen, F. S., Thygesen, P., Reedtz-Runge, S., & Kruse, T.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark
- Corresponding author
- Lau, Jesper
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-09-11
- Volume
- 58
- Issue
- 18
- Pages
- 7370-7380
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2162140339
- Cited by
- 1,105
- References
- 36
- Citations by year
- 2026: 160 · 2025: 193 · 2024: 151 · 2023: 97 · 2022: 106 · 2021: 84 · 2020: 88 · 2019: 71 · 2018: 77 · 2017: 46 · 2016: 30 · 2015: 2
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, liraglutide, glucagon-like peptide-1 analogues, GLP-1 receptor, albumin binding, weekly dosing, plasma half-life, metabolic stability, fatty acid acylation, type 2 diabetes, obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Cell Line, Glucagon-Like Peptides, Half-Life, Cricetinae, Humans, Injections, Subcutaneous, Male, Mice, Obese, Models, Molecular, Structure-Activity Relationship, Swine, Swine, Miniature, Rats, Sprague-Dawley, Crystallography, X-Ray, Glucagon-Like Peptide 1, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.